Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications

被引:0
|
作者
Steingrimsdottir, H [1 ]
Gruber, A
Björkholm, M
Svensson, A
Hansson, M
机构
[1] Karolinska Hosp, Dept Med, Div Hematol, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Stockholm, Sweden
[3] Karolinska Hosp, Dept Clin Immunol & Transfus Med, SE-17176 Stockholm, Sweden
关键词
autologous stem cell transplantation; immune reconstitution; hematopoietic reconstitution; infectious complication; lymphocyte subset recovery;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives. Autologous peripheral stem cell transplantation (APSCT) is increasingly used for various hematologic malignancies and sol; id tumors. The objective of this study was to analyze the immune reconstitution after APSCT and see ii there was any correlation with diagnosis, age, type of high-dose therapy, CD34(+) selection of the autograft and double vs single APSCT. Design and Methods. Lymphocyte subset recovery was studied in 46 consecutive patients with hematologic malignancies and breast cancer, who underwent APSCT. Eleven patients with multiple myeloma received tandem autografts. Thirty-one patients were given total body irradiation (TBI) as part of the high-dose treatment. Eighteen patients received a CD34(+) selected graft. The percentage and absolute numbers of lymphocyte populations, T-cells (CD2(+), CD3(+)), B-cells (CD19(+)), NK cells (CD56(+) CD3(-) and CD16(+)CD3(-)) and T-cell subpopulations [CD4(+), CD8(+), CD4(+)CD45RA(+), CD4(+) CD45RO(+), CD4(+)DR(+), CD8(+) CD45RO(+), CD8(+)DR(+)), were monitored with Row cytometry during the first year after APSCT. Results. The total B-cell (CD19(+)) and T-cell (CD3(+)) counts were reconstituted to normal levels 2-4 months after APSCT. All patients had a low CD4/CD8 ratio during the observation period, related to both a low number of CD4(+) cells and elevated numbers of CD8(+) cells. The low number of CD4(+) cells was due to a persistently low level of naive CD4(+)CD45RA(+) cells. A high proportion of the CD8(+) cells displayed a phenotype compatible with activated T-cells (CD8(+)DR(+)) up to 10 months after autografting. The number of NK cells (CD56(+)3(-) or CD16(+)3(-)) reached normal values within one month post-transplant. No single variable, such as diagnoses, age, TBI as part of the high-idose treatment, tandem autografting or CD34(+) selection of the graft, influenced the immune or hematopoietic reconstitution and no correlation with documented infectious complications was found. Interpretation and Conclusions. Despite heterogeneity of diseases, age, initial treatment and high-dose regimens, lymphocyte subset analysis did not reveal any differences in hematopoietic or immune reconstitution. AII patients had a low CD4(+)/CD8(+) ratio during at least the first year post-transplant, caused by a persistent increase of CD8(+) lymphocytes and a constant reduction of CD4(+) lymphocytes, making the patients susceptible to infections for a prolonged period of time post-transplant. (C)2000, Ferrata Storti Foundation.
引用
收藏
页码:832 / 838
页数:7
相关论文
共 50 条
  • [21] Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation
    Chen, BJ
    Cui, XY
    Sempowski, GD
    Domen, J
    Chao, NJ
    [J]. BLOOD, 2004, 103 (11) : 4344 - 4352
  • [22] Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors
    Jathavedam, Ashwin
    Feldman, Darren R.
    Ishill, Nicole
    Turkula, Stefan
    Patil, Sujata
    Bosl, George J.
    Motzer, Robert J.
    Weinstock, David M.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (05) : 595 - 600
  • [23] Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma
    Merryman, Reid W.
    Redd, Robert
    Jeter, Erin
    Wong, Jeff L.
    McHugh, Kristin
    Reynolds, Carol
    Nazzaro, Matthew
    Varden, Aine
    Brown, Jennifer R.
    Crombie, Jennifer L.
    Davids, Matthew S.
    Fisher, David C.
    Jacobsen, Eric
    Jacobson, Caron A.
    Kim, Austin, I
    LaCasce, Ann S.
    Ng, Samuel Y.
    Odejide, Oreofe O.
    Parry, Erin M.
    Dahi, Parastoo B.
    Nieto, Yago
    Joyce, Robin M.
    Chen, Yi-Bin
    Herrera, Alex F.
    Armand, Philippe
    Ritz, Jerome
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (01): : 32.e1 - 32.e10
  • [24] THE ROLE OF HIGH-DOSE THERAPY AND AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA
    STEWART, DA
    VOSE, JM
    WEISENBURGER, DD
    ANDERSON, JR
    RUBY, EI
    BAST, MA
    BIERMAN, PJ
    KESSINGER, A
    ARMITAGE, JO
    [J]. ANNALS OF ONCOLOGY, 1995, 6 (03) : 263 - 266
  • [25] Immune reconstitution after high dose therapy with autologous blood stem cell support.
    Steingrimsdottir, H
    Gruber, A
    Bjorkholm, M
    Svensson, A
    Hansson, M
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 : S130 - S130
  • [26] Role of palifermin for autologous hematopoietic stem cell transplantation after conditioning with high-dose melphalan
    Verraes, Kristof
    Delforge, Michel
    [J]. ACTA CLINICA BELGICA, 2010, 65 (06): : 457 - 457
  • [27] Endocrine complications of high-dose therapy with stem cell transplantation
    Sanders, JE
    [J]. PEDIATRIC TRANSPLANTATION, 2004, 8 : 39 - 50
  • [28] Infectious complications after high-dose chemotherapy and autologous stem cell transplantation, acute and oneyear infection-associated mortality
    Ruhnke, M.
    Weigel, A.
    Ziad, I
    Lechtenberg, L.
    Eckstein, N.
    Mikolajewska, A.
    [J]. ONKOLOGIE, 2013, 36 : 83 - 83
  • [29] Early infectious complications after high-dose chemotherapy and stem cell transplantation for haematological malignancies
    Stojanoski, Z
    Pivkova, A
    Cevreska, L
    Siljanoski, N
    Karanfilski, O
    Panovska, I
    Ivanovski, M
    Georgievski, B
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 : S319 - S320
  • [30] The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation
    Phillips, GL
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (06) : 53 - 56